Healthcare Industry News: Neoprobe
News Release - June 24, 2008
Neoprobe Introduces Enhanced Gamma Detection System
New Control Unit Features Internal Wireless LinkDUBLIN, Ohio--(HSMN NewsFeed)--Neoprobe Corporation (OTCBB: NEOP ), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it has recently introduced an enhanced gamma detection control unit, the Neoprobe® GDS (Model 2300), in connection with the Company’s marketing partner, Ethicon Endo-Surgery, Inc. (a Johnson & Johnson company). The Neoprobe GDS control unit contains internal circuitry that enables it to communicate with Neoprobe’s family of wireless probes without the necessity of an external adapter. Neoprobe’s wireless gamma detection products are based on Bluetooth® technology and eliminate cumbersome cables that can unnecessarily complicate the surgical field. Neoprobe’s wireless probes are available with either straight or angled tips and can also be used with all previous models of the Company’s neo2000® control unit (Models 2000, 2100 and 2200) using an external serial port adapter. Neoprobe’s gamma detection products are widely used by cancer surgeons in a procedure called Sentinel Lymph Node Biopsy (SLNB) or Intraoperative Lymphatic Mapping (ILM).
David Bupp, Neoprobe’s President and CEO, said, “We are excited by this addition to our gamma detection product line. Our wireless gamma detection probes have been well received in the marketplace and placements over the last eighteen months have exceeded our initial expectations. The improvements to our wireless product offerings, coupled with our clinical development program for the lymphatic tissue tracing agent Lymphoseek®, further demonstrate our ongoing commitment to assist physicians in providing state of the art treatment for cancer patients.”
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000® line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix® line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.Neoprobe.com
Source: Neoprobe
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
